In the NOBORI Biolimus-Eluting Versus XIENCE V/PROMUS Everolimus-Eluting Stent Trial ( NEXT ) , a formal OCT substudy investigated 91 patients ( 55 EES-treated lesions in 48 patients and 51 BES-treated lesions in 43 patients ) with 8-12 months follow-up imaging at 18 centers .